Additionally, our analyses revealed that CRC patients in the low-risk group had a favorable response to the treatment of 5-Fluorouracil and CTLA-4 blocker, which suggested that the 6-SLC gene signature could also be well applied to choose individualized therapies for CRC. Here, CTLA4 is linked to colorectal carcinoma.